Pages that link to "Q34194743"
Jump to navigation
Jump to search
The following pages link to IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. (Q34194743):
Displaying 50 items.
- Cytosine modifications in neurodevelopment and diseases (Q26852087) (← links)
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma (Q26995506) (← links)
- Unlocking epigenetic codes in neurogenesis (Q26998460) (← links)
- Contemporary murine models in preclinical astrocytoma drug development (Q27026937) (← links)
- 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS (Q28087807) (← links)
- Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification (Q28383205) (← links)
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients (Q30300114) (← links)
- Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas (Q33753426) (← links)
- ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples (Q33757037) (← links)
- Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma (Q34308674) (← links)
- MTA1--a stress response protein: a master regulator of gene expression and cancer cell behavior (Q34573808) (← links)
- Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity. (Q34848038) (← links)
- Transcriptional analysis of aggressiveness and heterogeneity across grades of astrocytomas (Q35022908) (← links)
- Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients (Q35067733) (← links)
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas (Q35204658) (← links)
- Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas (Q35675684) (← links)
- DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status (Q35760603) (← links)
- How molecular testing can help (and hurt) in the workup of gliomas (Q35770275) (← links)
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors (Q35811255) (← links)
- IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. (Q35845197) (← links)
- Comparative transcriptomics reveals similarities and differences between astrocytoma grades (Q35870174) (← links)
- TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline (Q36261882) (← links)
- Targeting cancer metabolism (Q36330869) (← links)
- Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas (Q36494326) (← links)
- IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. (Q36557547) (← links)
- IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas (Q36557573) (← links)
- Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas (Q36737930) (← links)
- What do we know about IDH1/2 mutations so far, and how do we use it? (Q36788229) (← links)
- AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. (Q37161304) (← links)
- World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages (Q37170743) (← links)
- Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma (Q37377830) (← links)
- An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas (Q37403150) (← links)
- cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome (Q37435393) (← links)
- The molecular landscape of diffuse glioma and prospects for biomarker development (Q38155656) (← links)
- Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. (Q38168686) (← links)
- Pharmacologic therapies for malignant glioma: a guide for clinicians. (Q38268897) (← links)
- The evolving molecular genetics of low-grade glioma (Q38349169) (← links)
- Glioblastoma: pathology, molecular mechanisms and markers (Q38460865) (← links)
- Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. (Q38526029) (← links)
- Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas (Q38684835) (← links)
- The new WHO 2016 classification of brain tumors-what neurosurgeons need to know (Q39091307) (← links)
- Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors (Q39298204) (← links)
- Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients (Q39961874) (← links)
- Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies (Q41536288) (← links)
- Identification of Histological Correlates of Overall Survival in Lower Grade Gliomas Using a Bag-of-words Paradigm: A Preliminary Analysis Based on Hematoxylin & Eosin Stained Slides from the Lower Grade Glioma Cohort of The Cancer Genome Atlas (Q42314430) (← links)
- Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". (Q42685111) (← links)
- Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma (Q47222464) (← links)
- Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. (Q47406043) (← links)
- Prognostic relevance of genetic alterations in diffuse lower-grade gliomas (Q47583690) (← links)
- MR Elastography Analysis of Glioma Stiffness and IDH1-Mutation Status (Q47999200) (← links)